Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127829 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
A Phase 1 study of Tumors, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT00127829: Completed Phase 1 study of Tumors, sponsored by AstraZeneca.
NCT00127829 is a Phase 1 study of Tumors that has completed, run by AstraZeneca. The registered enrollment target is 66 participants, below the 196-participant average among 20 other Tumors trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00127829, a Phase 1 study of Tumors, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
Conditions Studied
Interventions
- DRUG Gefitinib
Study Locations (2)
California
- Research Site - Los Angeles
- Research Site - Palm Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00127829 record still lists
NCT00127829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 196-participant average among 20 other Tumors trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Gefitinib is the first listed.
NCT00127829 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00127829 about?
NCT00127829 is a clinical study titled "Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic". This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
What is the current status of trial NCT00127829?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2005-07. Estimated completion is 2008-01.
What conditions does trial NCT00127829 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00127829?
The interventions under investigation include: Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00127829?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00127829 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00127829's enrollment target sits among peer trials
66 11th of 20 higher than 10 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia